Profile data is unavailable for this security.
About the company
Nuformix plc is a United Kingdom-based pharmaceutical development company. The Company is engaged in targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing, and patenting novel drug forms, with improved physical properties, to develop new products that are differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Its clinical pipeline includes NXP001, NXP002 and NXP004. NXP001 is pursuing licensing opportunities. NXP002 is its pre-clinical lead asset and a potential inhaled treatment for idiopathic pulmonary fibrosis (IPF) and possibly other fibrosing interstitial lung diseases (ILDs). NXP004 is a form of Olaparib, which is used for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation.
- Revenue in GBP (TTM)0.00
- Net income in GBP-436.95k
- Incorporated2015
- Employees2.00
- LocationNuformix PLC6th Floor, 60 Gracechurch StreetLONDON EC3V 0HRUnited KingdomGBR
- Phone+44 122 362 7222
- Websitehttps://nuformix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ovoca Bio PLC | 0.00 | -2.00m | 612.97k | 5.00 | -- | 0.1413 | -- | -- | -0.0245 | -0.0245 | 0.00 | 0.0532 | 0.00 | -- | -- | 0.00 | -27.00 | -17.82 | -32.86 | -19.39 | -- | -- | -- | -- | 4.68 | -48.64 | 0.00 | -- | -- | -- | -6.96 | -- | -- | -- |
| Voyager Life PLC | 314.00k | -1.10m | 630.13k | 28.00 | -- | 0.9933 | -- | 2.01 | -0.0912 | -0.0912 | 0.0253 | 0.044 | 0.1897 | 1.58 | 3.85 | 11,214.29 | -66.51 | -- | -77.02 | -- | 41.72 | -- | -350.64 | -- | 2.83 | -69.50 | 0.4625 | -- | 59.55 | -- | -38.70 | -- | -- | -- |
| Nuformix PLC | 0.00 | -436.95k | 1.43m | 2.00 | -- | 0.3105 | -- | -- | -0.0006 | -0.0006 | 0.00 | 0.0056 | 0.00 | -- | -- | -- | -9.50 | -- | -9.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| ReNeuron Group Plc | 249.00k | -5.07m | 1.93m | 34.00 | -- | 0.7966 | -- | 7.75 | -0.0888 | -0.0888 | 0.0044 | 0.0424 | 0.0246 | -- | 0.6442 | 7,323.53 | -50.10 | -43.12 | -101.09 | -58.50 | -- | -- | -2,037.35 | -714.73 | -- | -- | 0.1247 | -- | 31.51 | 65.26 | 44.18 | -- | -1.31 | -- |
| N4 Pharma PLC | 1.95k | -1.28m | 2.15m | 5.00 | -- | 1.91 | -- | 1,102.69 | -0.0053 | -0.0053 | 0.00001 | 0.0042 | 0.0011 | -- | 0.009 | 390.00 | -74.20 | -57.05 | -79.41 | -61.13 | -- | -- | -65,475.90 | -309,312.80 | -- | -- | 0.00 | -- | -- | -51.52 | -24.05 | -- | -- | -- |
| Hellenic Dynamics PLC | -100.00bn | -100.00bn | 2.96m | 25.00 | -- | 3.73 | -- | -- | -- | -- | -- | 0.006 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.3029 | -- | -- | -- | -- | -- | -- | -- |
| Fusion Antibodies PLC | 1.58m | -2.84m | 3.19m | 50.00 | -- | 1.37 | -- | 2.02 | -0.0861 | -0.0861 | 0.0436 | 0.0245 | 0.5229 | 3.15 | 1.88 | 31,580.00 | -93.94 | -31.29 | -130.56 | -37.72 | -7.41 | 42.58 | -179.67 | -48.25 | 2.32 | -- | 0.0313 | -- | -39.55 | 1.52 | -116.33 | -- | -23.83 | -- |
| TheraCryf PLC | 838.00k | -3.35m | 3.21m | 7.00 | -- | 0.5239 | -- | 3.82 | -0.0122 | -0.0122 | 0.0031 | 0.0143 | 0.1406 | -- | 1.81 | 119,714.30 | -56.25 | -42.37 | -60.57 | -46.32 | -- | -- | -400.12 | -2,324.84 | -- | -- | 0.00 | -- | -- | -- | -48.10 | -- | -32.24 | -- |
| Oxford Cannabinoid Tchnlgs Hldngs PLC | 0.00 | -4.24m | 3.76m | 7.00 | -- | 1.70 | -- | -- | -0.0044 | -0.0044 | 0.00 | 0.002 | 0.00 | -- | -- | 0.00 | -82.98 | -56.41 | -104.70 | -66.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.16 | -- | -- | -- |
| IXICO PLC | 6.67m | -1.18m | 3.93m | 89.00 | -- | 0.3436 | -- | 0.5894 | -0.0244 | -0.0244 | 0.138 | 0.2364 | 0.4822 | -- | 2.82 | 74,887.64 | -8.52 | 4.35 | -9.57 | 5.33 | 49.06 | 62.09 | -17.67 | 6.61 | -- | -- | 0.0327 | 0.00 | -22.89 | 4.32 | -214.15 | -- | 92.12 | -- |
| ValiRx Plc | 0.00 | -2.41m | 4.30m | 8.00 | -- | 0.791 | -- | -- | -0.0256 | -0.0256 | 0.00 | 0.0411 | 0.00 | -- | -- | 0.00 | -69.67 | -58.85 | -69.21 | -68.96 | -- | -- | -- | -- | -- | -575.81 | 0.0072 | -- | -- | -- | -55.87 | -- | -- | -- |
| BSF Enterprise PLC | 12.94k | -1.50m | 5.17m | 4.00 | -- | 1.06 | -- | 399.29 | -0.0159 | -0.0159 | 0.0001 | 0.047 | 0.0028 | 2.11 | 0.0837 | 3,235.00 | -32.30 | -- | -34.46 | -- | -451.16 | -- | -11,600.08 | -- | 8.16 | -154.86 | 0.0313 | -- | -- | -- | -61.40 | -- | -- | -- |
